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Abstract
Background: Serum protein profiling seems promising for early detection of breast cancer. However,
the approach is also criticized, partly because of difficulties in validating discriminatory proteins. This
study's aim is to validate three proteins previously reported to be discriminative between breast cancer
cases and healthy controls. These proteins had been identified as a fragment of inter-alpha trypsin inhibitor
H4 (4.3 kDa), C-terminal-truncated form of C3a des arginine anaphylatoxin (8.1 kDa) and C3a des arginine
anaphylatoxin (8.9 kDa).
Methods: Serum protein profiles of 48 breast cancer patients and 48 healthy controls were analyzed with
surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS).
Differences in protein intensity between breast cancer cases and controls were measured with the Mann-
Whitney U test and adjusted for confounding in a multivariate logistic regression model.
Results: Four peaks, with mass-to-charge ratio (m/z) 4276, 4292, 8129 and 8941, were found that were
assumed to represent the previously reported proteins. M/z 4276 and 4292 were statistically significantly
decreased in breast cancer cases compared to healthy controls (p < 0.001). M/z 8941 was decreased in
breast cancer cases (p < 0.001) and m/z 8129 was not related with breast cancer (p = 0.87). Adjustment
for sample preparation day, sample storage duration and age did not substantially alter results.
Conclusion: M/z 4276 and 4292 both represented the previously reported 4.3 kDa protein and were
both decreased in breast cancer patients, which is in accordance with the results of most previous studies.
M/z 8129 was in contrast with previous studies not related with breast cancer. Remarkably, m/z 8941 was
decreased in breast cancer cases whereas in previous studies it was increased. Differences in patient
populations and pre-analytical sample handling could have contributed to discrepancies. Further research
is needed before we can conclude on the relevance of these proteins as breast cancer biomarkers.
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Background
In the search for new breast cancer biomarkers several
studies have been performed comparing serum protein
profiles of breast cancer cases with those of healthy con-
trols using surface enhanced laser desorption/ionization
time-of-flight mass spectrometry (SELDI-TOF MS) [1-5].
In these studies several proteins have been found to be
linked with the presence of a breast tumor. However, only
occasionally the same proteins are found to be associated
with the disease state [1,4,5]. This is likely to be caused by
the use of different protocols for sample handling, sample
preparation and sample storage as well as the use of differ-
ent ProteinChip arrays and binding- and wash buffers.
However, even in validation studies using identical proto-
cols, it has not been possible to replicate the results of pre-
vious studies entirely [2,4]. Differences in results may be
caused by chance; simply because a large number of peaks
is tested some proteins will be found to discriminate
between breast cancer cases and healthy controls. Also dif-
ferences between the patient populations (like in age) and
in characteristics of the tumors may have led to different
results.
For instance, in 2002 Li et al. [3] performed a study to
identify serum biomarkers for invasive breast cancer. In
this study three proteins with masses of 4.3 kDa, 8.1 kDa
and 8.9 kDa were found that were together able to dis-
criminate best between breast cancer cases and non-can-
cer controls. The non-cancer control group in this study
consisted of both women with benign breast disease and
healthy controls. The 4.3 kDa protein was decreased in
breast cancer cases compared to non-cancer controls, the
8.1 and 8.9 kDa proteins were both increased [3].
In 2005, Mathelin et al. [2] performed a study to validate
the results of Li et al. [3] with different samples in a differ-
ent laboratory using the same assay. In this study five
peaks were found which masses corresponded to those of
the proteins found by Li et al. [2,3]. Two peaks probably
representing the 4.3 kDa protein and its oxidized form
(m/z (mass-to-charge ratio) of 4286 and 4302) were both
statistically significantly decreased in breast cancer cases
compared to non-cancer controls (women with benign
breast disease and healthy controls). Two peaks that could
possibly represent the 8.9 kDa protein (m/z of 8919 and
8961) were both statistically significantly increased in
breast cancer cases compared to non-cancer controls [2].
Above mentioned findings are in accordance with those of
Li et al. [3]. Contrary, the intensity of the peak likely to
represent the 8.1 kDa protein (m/z of 8129) was not dif-
ferent between breast cancer cases and non-cancer con-
trols in this study [2].
At the same time, Li et al. also performed a validation
study [4] of the candidate biomarkers previously reported
by their group. They used different samples but analyzed
them in the same laboratory using the same assay. In this
study women with benign breast disease were included as
cases, together with women with ductal carcinoma in situ
(DCIS) or stage I, II or III breast cancer. Three peaks with
masses similar to those of the previously reported proteins
were found to be discriminative between cases and con-
trols. Strikingly, in this study the 4.3 kDa peak was
increased in cases compared to controls, instead of
decreased. The 4.3 kDa peak was identified in this study as
a fragment of inter-alpha trypsin inhibitor heavy chain H4
(ITIH4). The 8.1 and 8.9 kDa peaks were again both
increased in cases compared to controls and were identi-
fied in this study as a C-terminal-truncated form of C3a
des arginine anaphylatoxin (C3adesArgΔ88) and C3a des
arginine anaphylatoxin (C3adesArg), respectively [4].
Poteintial limitations of these studies include differences
between cases and controls in storage duration [3] and age
[2,3]. In the present study we analyzed samples of cases
and controls, who were frequency matched for age at
intake and storage duration of their serum sample, with
the same protocol. With this study we aimed to determine
whether the three previously reported proteins [2-4] are
truly discriminative between breast cancer cases and
healthy controls, after adjustment for any differences in
age and storage duration.
Methods
Study population
We performed a case-control study with 48 women (aged
25 to 88 years) diagnosed with primary invasive breast
cancer and 48 healthy controls (healthy female relatives
or friends of the patients who accompanied them to the
hospital). Cases and controls were frequency matched
regarding their age and the storage duration of their serum
sample as much as possible. Age and menopausal status
of the cases were obtained through examination of the
medical records. Tumor type, tumor size, tumor differen-
tiation, lymph node involvement metastasis, oestrogen
receptor (ER) and progesterone receptor (PR) status and
HER2/neu and p53 expression were determined by path-
ological examination.
Serum samples of the cases and controls, which were col-
lected between January 2003 and June 2005, were
obtained from a serum bank at The Netherlands Cancer
Institute (NKI), Amsterdam, The Netherlands. These
serum samples were collected after receiving individuals'
informed consent under approval of the Institutional
Review Board Control. Serum samples of the cases were
obtained after diagnosis of breast cancer and before sur-
gery or any other kind of treatment. Blood collection,
processing and storage of the serum samples was per-
formed under strictly defined conditions which were theBMC Medical Genomics 2009, 2:4 http://www.biomedcentral.com/1755-8794/2/4
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same for cases and controls. All serum samples were col-
lected with the use of BD Vacutainer SST plastic serum
tubes with clot activator and gel (Becton-Dickinson, Fran-
klin Lakes, NJ, USA). After collection, blood samples were
allowed to clot for 30 minutes at room temperature and
were subsequently centrifuged for 15 minutes at 3000
rpm at room temperature. Thereafter, samples were aliq-
uoted and stored at -30°C.
Protein profiling
We executed the same sample preparation protocol and
used the same ProteinChip arrays (IMAC30 activated with
nickel; Bio-Rad Laboratories, Hercules, Ca, USA) and
wash- and binding buffers as described by Li et al. [3]. A
minor difference is that in this study unsaturated instead
of saturated sinapinic acid (SPA; Bio-Rad Laboratories)
was used, prepared according to manufacturer's instruc-
tion.
Samples of breast cancer cases and controls were alter-
nately and in duplicate manually applied to the arrays.
Half of the case samples and half of the control samples
were prepared and applied to the array on day 1 and the
other half of the case and control samples were prepared
and applied to the array on day 2. Detection of the pro-
teins bound to the arrays was performed with SELDI-TOF
MS for all arrays on the same day. For this we used the
newest SELDI-TOF MS instrument, the PCS 4000 Protein-
Chip Reader, the enterprise edition (Bio-Rad Laborato-
ries). Contrary to the first generation instruments, the PCS
4000 has an increased dynamic range of the detector. This
means that it has no fixed maximal signal and therefore
saturation of the detector is less likely to occur. Further-
more, instead of using arbitrary units, peak intensities are
scaled in μA, corresponding to the real electric current
generated by the impact of ions onto the detector [6].
At the ProteinChip Reader, 10 shots with an intensity of
4500 nJ were fired on every fourth position of the entire
spot. The detector attenuation was set to 1000 Da and
masses up to 200,000 Da were detected with a focus at
8000 Da. The m/z was calibrated externally with an All-in-
1 standard peptide mixture containing vasopression
(1084.3 Da), somatostatin (1637.9 Da), dynorphin
(2147.5 Da), ACTH 1–24 (2933.5 Da), bovine insulin
beta-chain (3495.9 Da), human insulin (5807.7 Da) and
recombinant hirudin (6963.5 Da) (Bio-Rad Laborato-
ries). Data were analyzed with the ProteinChip Software
package, version 3.1 (Bio-Rad Laboratories). Baseline sub-
traction was applied to the spectra and intensities of
masses between 3,000 and 200,000 Da were normalized
to the average total ion current (TIC) of all spectra. Ion
noise from the matrix passed through in the spectra up to
3,000 Da and therefore this region was excluded from the
analysis. Spectra with a very high or low TIC were elimi-
nated from the analysis. This was the case if the normali-
zation factor (NF) of a spectrum deviated more than two
standard deviations (SD) from the mean NF.
With the Biomarker Wizard (BMW) software application
(Bio-Rad Laboratories), peaks with a signal-to-noise ratio
greater than 5 and which were present in at least 20% of
the spectra were auto-detected. Peak clusters were com-
pleted with peaks with a signal-to-noise ratio greater than
2, within a 0.3% mass window of the detected peaks. In
the spectra with no peak in a detected peak cluster, a mark
was placed at the average m/z of that peak cluster. In the
duplicate spectra of a subject, the intensities of the peaks
with the same mass were averaged. To estimate the repro-
ducibility of these duplicates the median coefficient of
variance (CV) and the inter-quartile range (IQR) was cal-
culated per m/z in cases and controls together.
Data analysis
The Mann-Whitney U test was used to test if the median
intensities of the detected peaks were statistically signifi-
cantly different (p-value < 0.01) between breast cancer
cases and healthy controls. The area under the ROC
(Receiver Operating Characteristic) curve (AUC) was esti-
mated per peak to evaluate the performance of a peak to
classify samples into the two groups.
The peaks with an m/z most similar to the mass of the pre-
viously reported proteins [2-4] were selected and all anal-
yses described below were performed on these peaks.
These peaks were most likely to represent the previously
reported proteins [2-4], also because these peaks were
detected under the same conditions as were used to detect
the previously reported proteins [2-4]. We analyzed the
same matrix (serum) on the same array type using the
same protocol. By doing this we did not only select those
proteins with the same mass, but also those binding under
the same conditions to the chip, indicating similarity in
pI.
In the control group we investigated whether age, the
duration of sample storage and day of sample preparation
influenced peak intensity. For this, we compared the
median intensities of the peaks between different catego-
ries of these variables with the Kruskal-Wallis test (>2 cat-
egories) or with the Mann-Whitney U test (2 categories).
To this end, controls were categorized according to tertiles
of age; < 49.3 years, 49.3 – 57.5 years or > 57.5 years and
were also categorized according to quartiles of sample
storage duration; < 12 months, 12 – 17 months, 18 – 31
months or > 31 months. Controls were also divided in
two groups according to day of sample preparation; day 1
or day 2. Subsequently, the Jonckheere-Terpstra test was
used to test if there was a trend in the median peak inten-BMC Medical Genomics 2009, 2:4 http://www.biomedcentral.com/1755-8794/2/4
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sities between the different categories of age and sample
storage duration.
To investigate whether any relationship between the
intensity of the peaks and the presence of a breast tumor
could be explained by above-mentioned variables, a logis-
tic regression analysis was performed, estimating the
crude odds ratio (OR) and the OR adjusted for these vari-
ables. For this purpose cases and controls were catego-
rized by tertiles of peak intensity (low, intermediate or
high intensity), based on the distribution in the control
group. Because the range in peak intensities strongly dif-
fered between samples prepared on day 1 and those pre-
pared on day 2, this was done separately for the set of
cases and controls prepared on day 1 and the set prepared
on day 2. Afterwards, the subjects in the same category in
the two sets were combined. We also performed a back-
ward logistic regression analysis in which we simultane-
ously included the peaks assumed to represent the
previously reported proteins [2-4] (continuous). Peaks
were removed from the model if they did not statistically
significantly contribute to the discrimination of cases and
controls.
To investigate whether the intensities of the peaks were
related to stage of disease, we tested if the median peak
intensities were different between categories of TNM
stage, tumor size, lymph node involvement and tumor
differentiation. We also tested if the peak intensities were
related to menopause status, hormone receptor status and
HER2/neu and p53 expression. The relation between
menopause status and peak intensities was investigated in
cases only, since no information about this variable was
available for the controls. To test these relations we used
the Kruskal-Wallis test or the Mann-Whitney U test,
dependent on number of categories. TNM stage was cate-
gorized as: IIA (n = 26), IIB (n = 11) or III (= IIIA + IIIC, n
= 11) and tumor size as: = 2 cm (n = 18) or > 2 cm (n =
30). Lymph node involvement was categorized as: no
regional lymph node metastasis (n = 9) or positive axillary
lymph nodes (n = 39). Tumor differentiation was classi-
fied into high and intermediate differentiation (n = 25) or
low differentiation (n = 22) (1 missing value). Menopause
status was categorized as pre- (n = 15) or postmenopausal
(n = 30) (2 missing values). ER and PR status were catego-
rized as ER- (n = 12) or ER+ (n = 35) and PR- (n = 19) or
PR+ (n = 28). HER2/neu and p53 expression was catego-
rized as HER2/neu- (n = 35) or HER2/neu+ (n = 12) and
p53- (n = 18) or p53+ (n = 23) (6 missing values). The
Jonckheere-Terpstra test was used to test if there was a
trend in the median peak intensities between the different
categories of TNM stage. For above mentioned statistical
analyses SPSS 12.0.1 was used and p-values < 0.05 were
considered statistically significant.
Results
Study population
The characteristics of the breast cancer cases and healthy
controls are presented in Table 1. The average age at time
of blood collection was 58 years for the cases and 53 years
for the controls. Sixty-three percent of the cases was post-
menopausal and 33% was premenopausal. The meno-
pausal status of two women was not reported in their
medical record. No information about menopause status
was available for the controls. For cases, the median dura-
tion between diagnosis and sample collection was 7 days
and all samples were collected before the start of treat-
ment. The median duration of sample storage until anal-
ysis was almost equal for the samples of the cases (16
months) and those of the controls (17 months).
More than half of the cases was affected with stage IIA
breast cancer and nearly a quarter of the cases was diag-
nosed with stage IIB breast cancer. Stage III breast cancer
was diagnosed in the other cases. More than 60% of the
tumors were larger than 2 cm and in more than 80% of
the cases the tumor had spread to the axillary lymph
nodes. Eighty-six percent of the tumors showed a low or
intermediate degree of differentiation (1 missing value).
None of the cases was diagnosed with distant metastases.
The majority of the tumors was ER+ (73%) and PR+
(58%). A quarter of the tumors showed an overexpression
of HER2/neu and half of the tumors had an overexpres-
sion of p53. For 6 cases (13%) p53 status was unknown.
These subjects were diagnosed in The Netherlands Cancer
Institute (NKI), however their surgery was performed in
another hospital. In those hospitals, the p53 status of the
tumor was not determined.
Peak detection
After normalization, 17 of the 192 spectra (48 cases and
48 controls in duplicate) were eliminated from the analy-
sis because their NF deviated more than two SD from the
mean NF. These spectra belonged to 10 controls and 6
cases. Of one case both spectra (both duplicates) had to
be eliminated. With the BMW software application, 45
peak clusters were auto-detected in the 175 left spectra, in
the mass-region between 3,000 Da and 200,000 Da. Sub-
sequently, in the duplicate spectra of a subject, the inten-
sities of the detected peaks with the same mass were
averaged. For the subjects with one spectrum left, only
peak intensities in that spectrum were used for analysis. A
Mann-Whitney U test performed on these (averaged) peak
intensities showed that the intensities of 20 of the 45
peaks were statistically significantly different between
breast cancer cases and healthy controls (p-value < 0.01).
These discriminatory peaks are listed in a table in Addi-
tional file 1 in order of m/z.BMC Medical Genomics 2009, 2:4 http://www.biomedcentral.com/1755-8794/2/4
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Table 1: Characteristics of the breast cancer cases, the healthy controls and their serum samples
Breast cancer cases
(n = 48)
Healthy controls
(n = 48)
Age (years)
Mean (± SD) 58 (± 14) 53 (± 9)
Menopause status, n (%)
Pre 16 (33) -
Post 30 (63) -
Missing 2 (4) 48 (100)
Sample storage duration (months)
Median (IQR) 16 (11–35) 17 (11–31)
Time from diagnosis to blood sampling (days)
Median (IQR) 7 (0–20)
Stage, n (%)
IIA 26 (54)
IIB 11 (23)
IIIA 6 (13)
IIIC 5 (10)
Tumor size, n (%)
> 0.5 – 1 cm 2 (4)
> 1 – 2 cm 16 (33)
> 2 – 5 cm 28 (58)
> 5 cm 2 (4)
Lymph node involvement, n (%)
No 9 (19)
1–3 29 (60)
> 3 10 (21)
Differentiation, n (%)
High 6 (13)
Intermediate 19 (40)
Low 22 (46)
Unknown 1 (2)
ER status, n (%)
Negative 13 (27)
Positive 35 (73)
PR status, n (%)
Negative 20 (42)
Positive 28 (58)
Her2/neu expression, n (%)
Negative 36 (75)
Positive 12 (25)
P53 expression, n (%)
Negative 18 (38)
Positive 24 (50)
Missing 6 (13)
SD = Standard Deviation, IQR = Inter-Quartile Range, ER = Oestrogen Receptor, PR = Progesterone ReceptorBMC Medical Genomics 2009, 2:4 http://www.biomedcentral.com/1755-8794/2/4
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Four peaks were detected which we assumed to represent
the three previously reported proteins [2-4] based on sim-
ilarities in mass and detected under the same conditions.
The median intensity of these peaks, as well as the p-value
of the Mann-Whitney U test and the AUCs are listed in
Table 2 in order of the m/z of the peaks. Two peaks were
detected that both were assumed to represent the previ-
ously reported protein of 4.3 kDa [2-4]. This protein was
identified by Li et al. [4] as a fragment of ITIH4 and has a
theoretical molecular weight (Mw) of 4285 Da. We based
this mass on the amino acid sequence reported by Song et
al. [7] and calculated it using ExPASy Proteomic Server
[8]. The two peaks found in our study had an m/z which
was almost similar to that Mw, namely 4276 and 4292.
The mass difference between these two peaks is 16 Da, the
exact mass of an oxygen-atom. The intensities of these two
peaks were also highly correlated (Pearson R2 = 0.834; p <
0.001 (in the control group)), indicating that they were
present in about the same ratio in every spectra. Conse-
quently, we assumed m/z 4276 to be the 4.3 kDa ITIH4
fragment and m/z 4292 to be the oxidized form of this
protein. Both these peaks should therefore be considered
for the comparison with the previously reported 4.3 kDa
protein [2-4]. The median intensity of both peaks was sta-
tistically significantly decreased in cases compared to con-
trols (11.04 [IQR: 2.10–29.31] versus 39.48 [IQR: 14.17–
77.58]; p < 0.0001 and 14.54 [IQR: 8.52–29.54] versus
42.07 [IQR: 29.67–63.39]; p < 0.0001, respectively).
One peak was found in this study that was assumed to
represent the previously reported protein of 8.1 kDa [2-4].
This protein was identified by Li et al. [4] as a C-terminal-
truncated form of C3adesArg. Its theoretical Mw is 8133 Da,
based on the amino acid sequence reported by Li et al. [4]
and calculated using ExPASy Proteomic Server [8]. The m/
z of the peak found in our study was almost identical to
that Mw, namely 8129. However, no difference in the
intensity of this peak was observed between cases and
controls (p = 0.87).
Also one peak was found that was assumed to represent
the previously reported protein of 8.9 kDa [2-4]. This pro-
tein was identified by Li et al. [4] as C3adesArg and has a
theoretical Mw of 8938 Da. We based this mass on the
amino acid sequence reported by Li et al. [4] and calcu-
lated it using ExPASy Proteomic Server [8]. The m/z of the
peak found in our study was almost identical to that Mw,
namely 8941. The intensity of this peak was statistically
significantly decreased in cases compared to controls
(31.27 [IQR: 24.07–44.88] versus 73.47 [IQR: 48.69–
86.72]; p < 0.0001). The small mass differences between
the theoretical masses of the previously found proteins
and the m/z of the peaks found in our study could be due
to the mass calibration of the ProteinChip Reader used.
Representative spectra from breast cancer cases and
healthy controls showing the four peaks found in this
study are presented in Fig. 1.
The median CV's per peak in cases and controls were 31%
[IQR: 15–62], 17% [IQR: 7–47], 11% [IQR: 5–22] and
13% [IQR: 5–23] for m/z 4276, 4292, 8129 and 8941,
respectively. The duplicate analyses were also investigated
separately and the results for the four peaks in the two
analyses were similar to each other and to the results of
the total analysis, i.e. the difference in intensity between
cases and controls was similar with comparable signifi-
cance levels (data not shown).
Influence of day of sample preparation, sample storage 
duration and age on peak intensities
The relations between peak intensities and day of sample
preparation, sample storage duration and age were esti-
mated in the control group. The results are presented in
Table 3.
A clear relation between peak intensity and day of sample
preparation was found for the peaks with an m/z of 4276,
4292 and 8129. The intensities of these peaks were statis-
tically significantly higher in control samples prepared on
Table 2: Intensities in cases and controls of the peaks most likely representing the previously reported proteins [2-4] in order of m/z
Breast cancer cases
(n = 47)
Healthy controls
(n = 48)
Mann-Whitney U test ROC-curve
M/z Median intensity IQR Median
intensity
IQR Intensity in cases vs. controls p-value AUC 95%CI
4276 11.04 2.10 – 29.31 39.48 14.17 – 77.58 Decreased <0.0001 0.716 0.61–0.82
4292 14.54 8.52 – 29.54 42.07 29.67 – 63.39 Decreased <0.0001 0.770 0.67–0.87
8129 25.92 20.48 – 28.19 26.05 21.06 – 28.08 - 0.870 0.510 0.39–0.63
8941 31.27 24.07 – 44.88 73.47 48.69 – 86.72 Decreased <0.0001 0.830 0.75–0.91
M/z = Mass to Charge ratio, IQR = Inter-Quartile Range, ROC-curve = Receiver Operating Characteristic curve, AUC = Area Under the Curve, 
95%CI = 95% Confidence IntervalBMC Medical Genomics 2009, 2:4 http://www.biomedcentral.com/1755-8794/2/4
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day 1 than those prepared on day 2. We also found a sta-
tistically significant trend in intensity over the four storage
duration categories for these three peaks, with lower
intensities in samples that were stored for a longer time.
Unintentionally, samples stored for less than 18 months
were all prepared on day 1 and samples stored for 18
months or more on day 2. Therefore, it is difficult to dis-
entangle the effects of day of preparation and storage
duration. Age was not significantly related to the intensity
of any of the peaks as shown in Table 3.
Relationships between peak intensities and the presence 
of breast cancer
The relationships between the intensities of the four peaks
and the presence of breast cancer, before and after adjust-
ment for day of sample preparation, sample storage dura-
tion and age are listed in table 4. For the peaks with an m/
z of 4276, 4292 and 8941, women with a low peak inten-
sity were statistically significantly more often affected with
breast cancer than women with a high peak intensity (ref-
erence group). The crude OR's with 95% CI (confidence
Representative SELDI-TOF MS spectra showing the intensity of the peaks with an m/z of 4276, 4292, 8129 and 8941 in breast  cancer cases and healthy controls Figure 1
Representative SELDI-TOF MS spectra showing the intensity of the peaks with an m/z of 4276, 4292, 8129 and 
8941 in breast cancer cases and healthy controls.BMC Medical Genomics 2009, 2:4 http://www.biomedcentral.com/1755-8794/2/4
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interval) for these three peaks were 6.0 [95% CI: 2.0–
18.2], 7.6 [95% CI: 2.4–24.3] and 13.0 [95% CI: 3.3–
50.8], respectively. Women with an intermediate peak
intensity for any of these three peaks were not more likely
to be affected with breast cancer than women in the refer-
ence group. The intensity of the peak with an m/z of 8129
was not related to the presence of breast cancer. After
adjustment for day of sample preparation, sample storage
duration and age results remained essentially the same.
Subsequently, we performed a backward logistic regres-
sion analysis in which we simultaneously included the
four peaks (continuous). M/z 8129 did not statistically
significantly contribute to the model. M/z 4276, m/z 4292
and m/z 8941 all contributed statistically significantly to
the discrimination of cases and controls (data not
shown).
Relationships between peak intensities and tumor 
characteristics and menopause status
The relations between the intensities of the four peaks and
tumor stage, tumor size, lymph node involvement and
tumor differentiation are shown in Table 5. The median
intensities of the peaks with an m/z of 4276 and 4292 in
cases without lymph node involvement were higher than
in cases with lymph node involvement (m/z 4276: 24.34
[IQR: 5.99–72.28] versus 8.66 [IQR: 1.87–24.37] and m/z
4292: 25.69 [IQR: 9.91–54.35] versus 13.13 [IQR: 5.97–
23.74], although not statistically significantly (p = 0.14
and p = 0.14). No statistically significantly relations were
observed between the intensities of the four peaks and any
of the other tumor characteristics.
The relations between the intensities of the four peaks and
menopause status, hormone receptor status and HER2/
neu and p53 expression are listed in Table 6. For m/z
8129, a statistically significantly decrease in intensity was
observed in postmenopausal cases compared to premen-
opausal cases (25.3 [IQR: 17.8–26.6] versus 27.6 [IQR:
22.2–32.7]; p = 0.03). In cases with p53– tumors com-
pared to cases with p53+ tumors, the decrease in intensity
for  m/z  8129 was borderline statistically significantly
(23.7 [IQR: 17.6–26.8] versus 26.5 [IQR: 24.8–30.1]; p =
0.07). No other statistically significant relation was found.
Table 3: Intensities of the peaks per day of sample preparation, category of sample storage duration and age group in healthy controls
M/z 4276 M/z 4292 M/z 8129 M/z 8941
n Median intensity (IQR) Median intensity (IQR) Median intensity (IQR) Median intensity (IQR)
Day of sample preparation
Day 1 24 74.04
(47.56–103.27)
62.78
(45.17–79.91)
27.39
(22.79–29.62)
78.94
(45.96–84.49)
Day 2 24 24.83
(9.58–38.24)
34.61
(28.54–39.32)
22.65
(18.02–26.89)
72.85
(50.43–105.05)
p-value* 48 <0.001 0.001 0.008 0.853
Sample storage
duration (months)
≤ 11 13 75.81
(33.59–118.06)
63.48
(37.10–79.58)
27.54
(21.94–31.63)
57.48
(43.11–79.66)
12–17 11 72.28
(50.60–87.56)
62.11
(46.25–83.88)
27.24
(24.70–29.87)
81.30
(52.43–99.14)
18–31 12 32.33
(12.37–40.50)
33.99
(25.21–45.65)
23.66
(15.58–27.08)
62.97
(42.67–111.06)
≥ 32 12 16.43
(8.38–35.85)
34.77
(29.84–37.99)
22.18
(20.46–26.89)
73.47
(52.76–105.05)
p-value# 48 0.001 0.011 0.063 0.620
p-trend† 48 <0.001 0.003 0.032 0.423
Age (yrs)
< 49.3 16 45.26
(19.00–77.58)
46.38
(31.02–62.95)
25.15
(21.29–27.55)
73.84
(49.50–84.49)
49.3–57.5 16 19.79
(8.38–62.11)
35.78
(28.52–63.14)
24.90
(21.98–27.62)
69.16
(39.17–85.8)
> 57.5 16 45.90
(23.58–85.81)
40.01
(30.47–72.05)
27.12
(20.43–33.59)
76.15
(56.15–101.64)
p-value# 48 0.346 0.680 0.753 0.850
p-trend† 48 0.583 0.940 0.438 0.880
M/z = Mass to Charge ratio, IQR = Inter-Quartile Range, * Mann-Whitney U Test, # Kruskal Wallis Test, † Jonckheere-Terpstra TestBMC Medical Genomics 2009, 2:4 http://www.biomedcentral.com/1755-8794/2/4
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Protein identity
The assumption that the proteins found in this study
indeed represent the previously reported proteins [2-4]
was based on similarities in the mass as well as on the con-
ditions under which these proteins were detected. How-
ever, there is also another indication to assume that m/z
4276 and m/z 4292 indeed represent the 4.3 kDa fragment
of the ITIH4 protein and its oxidized form. We found
three other peaks in this study which masses (m/z 3156,
m/z 3270 and m/z 3965) highly corresponded with the
theoretical masses of three other fragments of ITIH4 pre-
viously described by Villanueva et al. [9] and Song et al.
[7] (3158 Da, 3274 Da and 3972 Da). We based these the-
oretical masses on the amino acid sequences reported by
Villanueva et al. [9] and Song et al. [7] and calculated
them using ExPASy Proteomic Server [8]. The intensities
of m/z 3270 and m/z 3965 were highly correlated with the
intensities of m/z 4276 and m/z 4292 (m/z 3270 and m/z
4276: R2 = 0.812, m/z 3270 and m/z 4292: R2 = 0.722, m/z
3965 and m/z 4276: R2 = 0.821 and m/z 3965 and m/z
4292: R2 = 0.756 [p < 0.001 for all]). This high correlation
in intensity is only expected when all these proteins origi-
nated from the same protein. Since masses of all these
proteins have very high resemblances with the theoretical
masses of the previously reported ITIH4 fragments and
these proteins were all detected under the same condi-
tions, we can assume that all these peaks represent frag-
ments of ITIH4.
The peak with an m/z  of 8941 was actually previously
identified in our laboratory in a breast cancer serum sam-
ple as C3adesArg. The method of protein identification was
similar to that performed in the validation study by Li et
al. [4]. The 8.9 kDa protein was purified using QhyperD
fractionation (Biosepra Inc., Malborough, MA, USA) and
concentrated on YM50 spin concentrators (Millipore, Bill-
erica, MA, USA). Subsequently, the eluate with the 8.9
kDa protein was de-salted on RP18 beads (Bio-Rad Labo-
ratories). This purification process was monitored by pro-
filing each fraction on IMAC30 Ni arrays and NP20 arrays
(a non-selective, silica chromatographic surface) (Bio-Rad
Laboratories). The de-salted eluate containing the 8.9 kDa
protein was subsequently subjected to SDS-PAGE analy-
sis. Gel electrophoresis was performed on Novex NuPage
gels (18% Tris-Glycine gel; Invitrogen, San Diego, CA,
USA). After staining, the band in the 8.9 kDa region was
excised and subjected to passive elution followed by tryp-
tic digestion of the eluate. Profiling of the gel-eluate on a
NP20 array confirmed the presence of the 8.9 kDa pro-
tein. Peptide mapping of the tryptic digest identified it as
complement component 3 precursor (estimated Z-score
1.57, 4% sequence coverage). Amino acid sequencing of 6
Table 4: The relationships between peak intensities and the presence of breast cancer before and after adjustment for sample 
characteristics and subject age
n Crude OR (95%CI) Adjusted OR* (95%CI)
cases controls
M/z 4276
Low intensity 36 16 6.0 (2.0–18.2) 5.3 (1.7–17.0)
Intermediate intensity 5 16 0.8 (0.2–3.3) 0.9 (0.2–3.7)
High intensity 6 16 1.0 (referent) 1.0 (referent)
M/z 4292
Low intensity 38 16 7.6 (2.4–24.3) 6.4 (1.8–22.3)
Intermediate intensity 4 16 0.8 (0.2–3.5) 0.7 (0.2–3.1)
High intensity 5 16 1.0 (referent) 1.0 (referent)
M/z 8129
Low intensity 13 16 0.8 (0.3–2.3) 0.7 (0.2–2.0)
Intermediate intensity 19 17 1.1 (0.4–2.9) 1.0 (0.4–2.8)
High intensity 15 15 1.0 (referent) 1.0 (referent)
M/z 8941
Low intensity 39 16 13.0 (3.3–50.8) 13.3 (3.2–55.0)
Intermediate intensity 5 16 1.7 (0.3–8.2) 1.8 (0.4–9.1)
High intensity 3 16 1.0 (referent) 1.0 (referent)
* OR's (odds ratios) with 95%CI (95% Confidence Interval) were adjusted for the following variables; day of preparation (day 1 or day 2), age 
(continuous) and storage duration (continuous).
M/z = Mass to Charge ratio, Tertiles of the intensities per peak were determined in the controls, separately for day of preparation, applied to cases 
prepared on the same day and afterwards combined in three categories.BMC Medical Genomics 2009, 2:4 http://www.biomedcentral.com/1755-8794/2/4
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peptides in the tryptic digest by tandem MS on a Q-TOF
identified the protein as C3a des-arginine anaphylatoxin
(C3adesArg, 61% sequence coverage), a protein with theo-
retical mass 8939.46 Da and pI 9.54. This identity was
confirmed by an immunoassay, for which ProteinA beads
were loaded with a C3a polyclonal antibody (Abcam Ltd,
Cambridge, UK).
Discussion
In this study including 48 breast cancer cases and 48
healthy controls we discovered four peaks with an m/z
(4276, 4292, 8129 and 8941) within the mass range of
the three previously reported proteins (4.3 kDa, 8.1 kDa
and 8.9 kDa) [2-4] using a similar analysis protocol [3].
Three of these four peaks were found to be discriminative
between breast cancer cases and healthy controls. The
peaks with an m/z of 4276, 4292 and 8941 were all statis-
tically significantly decreased in cases compared to con-
trols. The intensity of the peak with an m/z of 8129 was
not different between cases and controls. After splitting
our data of the two duplicates into two groups, results
were similar. This together with CV's within an acceptable
range indicates that our results are robust.
The peaks with an m/z of 4276 and 4292 were assumed to
represent a fragment of ITIH4 (the 4.3 kDa protein) and
its oxidized form. The decrease in intensity of the 4.3 kDa
protein in breast cancer cases reported in the study by Li
et al. [3] and in that by Mathelin et al. [2] was replicated
in our study. The increase in intensity of the 4.3 kDa pro-
tein found in the validation study by Li et al. [4] appears
to be an exception.
The 8.1 kDa protein, previously identified as
C3adesArgΔ88[4] was increased in breast cancer cases in both
studies by Li et al. [3,4]. This could not be replicated in
our study. In our study, no difference in intensity between
Table 5: Intensities of the peaks for different categories of the tumor characteristics
M/z 4276 M/z 4292 M/z 8129 M/z 8941
n Median intensity
(IQR)
Median intensity
(IQR)
Median intensity
(IQR)
Median intensity
(IQR)
TNM stage
IIA 26 13.00
(1.79–83.10)
19.51
(8.07–54.23)
26.27
(23.48–30.07)
33.56
(24.09–50.43)
IIB 10 4.97
(1.33–17.24)
11.44
(4.83–15.79)
25.44
(16.56–27.75)
30.49
(20.16–34.59)
III 11 11.88
(4.89–24.69)
15.86
(9.88–22.87)
25.70
(15.68–26.54)
37.55
(25.26–47.29)
p-value* 47 .340 .211 .203 .473
p-trend# 47 .553 .368 .075 .667
Tumor size
0.5–2 cm 18 10.24
(1.36–85.58)
18.44
(5.44–63.09)
26.53
(22.86–30.08)
30.48
(23.24–61.21)
> 2 cm 29 11.88
(3.97–24.51)
12.21
(8.71–24.28)
25.90
(19.08–27.45)
32.90
(24.04–44.16)
p-value† 47 .844 .526 .204 .896
Lymph node involvement
No 9 24.34
(5.99–72.28)
25.69
(9.91–54.35)
26.48
(23.33–30.29)
38.92
(27.68–53.99)
Yes 38 8.66
(1.87–24.37)
13.13
(5.97–23.74)
25.81
(18.87–27.65)
30.49
(23.30–43.31)
p-value† 47 .137 .144 .224 .224
Differentiation
High-Intermediate 25 11.04
(2.99–24.47)
14.06
(7.86–22.52)
25.72
(19.84–27.45)
31.27
(24.13–42.65)
Low 21 19.90
(2.98–60.12)
17.06
(8.71–44.18)
26.54
(19.68–29.79)
28.99
(23.34–45.88)
p-value† 46 .635 .384 .360 .903
M/z = Mass to Charge ratio, IQR = Inter-Quartile Range, * Kruskal Wallis Test, # Jonckheere-Terpstra Test, † Mann-Whitney U TestBMC Medical Genomics 2009, 2:4 http://www.biomedcentral.com/1755-8794/2/4
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breast cancer cases and controls was found for this pro-
tein, neither as it was in the study by Mathelin et al. [2].
In the three previous studies [2-4], the 8.9 kDa protein,
identified as C3adesArg was increased in breast cancer cases.
This could not be replicated in our study. In our study, this
protein was decreased in cases compared to controls,
which thus appears to be an exception. Remarkably, a
decrease of this protein was also found in two other breast
cancer sample-sets analyzed by our group (publication in
preparation). Furthermore, it is also remarkable that this
protein was the best discriminating protein between
breast cancer cases and healthy controls found in this
study. The 8941 m/z peak found in our study was previ-
ously identified by our group as C3adesArg, which is thus in
agreement with the identity of the 8.9 kDa protein found
in the validation study by Li et al. [4]. A summary of the
results of the several studies is presented in Table 7.
Li et al. [4] suggested that the inconsistency in regulation
of the 4.3 kDa peak (ITIH4 fragment) between their two
studies is caused by the instability of this protein. In their
first study [3], serum samples from breast cancer patients
were collected during a longer time interval than the con-
trol samples, whereas samples in the validation study [4]
were all collected within the same 2-year window. If the
instability of this protein causes further truncation during
prolonged storage, this would explain why the intensity of
this protein is lower in cases than in controls in Li's first
study [3]. In our study, however, as well as in that by
Mathelin et al. [2], storage duration of samples did not
differ between cases and controls and still in both studies
Table 6: Intensities of the peaks for different categories of hormone-receptor status, Her2/neu and P53 expression and menopause 
status
M/z 4276 M/z 4292 M/z 8129 M/z 8941
n Median intensity
(IQR)
Median intensity
(IQR)
Median intensity
(IQR)
Median intensity
(IQR)
ER status
Negative 12 15.2
(0.7–70.6)
18.3
(6.2–48.1)
26.3
(25.2–28.5)
39.9
(24.3–57.5)
Positive 35 11.0
(3.9–24.3)
14.5
(8.9–22.9)
25.7
(17.9–28.2)
30.5
(24.1–43.4)
p-value* 47 .961 .696 .421 .380
PR status
Negative 19 7.1
(4.0–29.3)
10.9
(8.5–30.8)
26.0
(21.7–27.8)
31.3
(24.0–43.3)
Positive 28 14.6
(1.8–28.2)
15.4
(6.8–28.7)
25.8
(19.5–29.6)
32.1
(24.1–46.7)
p-value* 47 .649 .696 .762 .588
Her2/neu expression
Negative 35 11.0
(1.9–29.3)
15.9
(5.6–29.5)
25.9
(20.5–27.8)
32.9
(24.1–46.9)
Positive 12 9.5
(4.3–66.2)
11.1
(9.1–43.2)
26.0
(16.2–29.3)
29.7
(23.3–41.7)
p-value* 47 .961 .826 .751 .575
P53 expression
Negative 18 6.5
(1.6–24.3)
12.7
(5.3–31.3)
23.7
(17.6–26.8)
27.1
(17.7–42.6)
Positive 23 11.0
(4.7–29.4)
14.9
(8.9–29.5)
26.5
(24.8–30.1)
32.9
(27.8–60.8)
p-value* 41 .599 .546 .070 .172
Menopause status
Premenopausal 15 7.9
(1.9– 84.3)
12.2
(10.1–69.2)
27.6
(22.2–32.7)
29.0
(22.7–43.3)
Postmenopausal 30 10.2
(2.0–25.6)
14.3
(5.5–29.8)
25.3
(17.8–26.6)
32.1
(24.2–45.4)
p-value* 45 .942 .580 .030 .563
M/z = Mass to Charge ratio, IQR = Inter-Quartile Range, * Mann-Whitney U Test, ER = Oestrogen Receptor, PR = Progesterone ReceptorBMC Medical Genomics 2009, 2:4 http://www.biomedcentral.com/1755-8794/2/4
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a decrease was found in cases compared to controls.
Therefore, the increase of the 4.3 kDa protein found in the
validation study by Li et al. [4] cannot be explained by this
factor. Also differences in discriminatory power and/or
direction of the relation between the several studies for
the 8.1 and the 8.9 kDa protein cannot be explained by
above mentioned factor.
Another factor that is important for storage is the temper-
ature at which samples are stored. Although in several
studies no major differences in serum protein profiles
were observed after a storage period of 1–3 months at -
20°C, -80°C or liquid nitrogen [10-12], Engwegen et al.
[13] found that after a storage duration of 5 months at -
20°C compared to -70°C several peaks were significantly
increased in intensity. This shows the importance of stor-
ing samples at the lowest possible temperature when sam-
ples are stored for a prolonged time. Samples analyzed in
the studies by Li et al. [3] and Mathelin et al. [2] were
stored at -80°C and -20°C, respectively for an unknown
time. Samples analyzed in the validation study by Li et al.
[4] and in our study were stored at -30°C. Samples of both
cases and controls analyzed in the validation study by Li
et al. [4] were collected from 2000 on (publication of
results in 2005). In our study, samples of both the cases
and the controls were stored for less than three and a half
years. The exact influence of the differences in storage
temperature in combination with storage duration on
peak intensities cannot easily be predicted. This is because
the influence of these factors on the several proteins is
very diverse [14,15]. Over time the intensity of some pro-
teins will decrease because of fragmentation, while the
intensities of the fragments of these proteins will increase.
However, when these fragments are also very unstable,
their intensities could also decrease after a prolonged
time. On top of this, some proteins are more vulnerable
to degradation than others [14,15]. It is therefore difficult
to predict whether these factors have influenced the
results of the several studies.
Another, possibly more likely explanation for the discrep-
ant results found in the several studies is differences in
pre-analytical sample handling. Several studies have
shown that the time between venipuncture and centrifu-
gation as well as the temperature at which samples are
held meanwhile is of major influence on protein profiles
[10,12-16]. When samples were held for a prolonged time
(more than 60 minutes) at room temperature, low mass
peaks were generated. These peaks were not formed as
long as samples were kept on ice [15]. Previous studies
also revealed that some proteins are more vulnerable to
sample handling than others [14,15]. Amongst others,
fragments of ITIH4 and C3a were found to be increased
more than 1.5-fold within 2 hours after venipuncture in
samples that were allowed to clot on room temperature
[15]. Samples of both cases and controls analyzed in our
study were pre-analytically handled identically following
a standard protocol. Samples were allowed to clot for 30
minutes at room temperature after which they were centri-
fuged for 15 minutes at 3000 rpm at room temperature.
All blood samples analyzed in the study by Mathelin et al.
[2] were allowed to clot at room temperature for a variable
duration (30–60 min) after which they were centrifuged
for 10 min at 3000 rpm at an unknown temperature. For
the studies by Li et al. [3,4] no information about clotting
and centrifugation conditions is available. It is also
unknown whether samples of cases and controls were pre-
analytically handled identically in these studies [3,4].
Table 7: Description of the peaks found in the different studies
Protein 1 Protein 2 Protein 3
Li et al. (2002) [3] kDa 4.3 ↓ 8.1 ↑ 8.9 ↑
AUC 0.846 0.795 0.934
p-value - - -
Mathelin et al. (2005) [2] M/z 4286 ↓ 4302 ↓ 8129 - 8919 ↑ 8961 ↑
AUC - - - - -
p-value# <0.000 <0.001 0.51 <0.02 <0.001
Li et al. (2005) Da ± 4300* ↑ 8116 ↑ 8926 ↑
Validation study [4] AUC - 0.65 0.71
p-value - - -
Current study M/z 4276 ↓ 4292 ↓ 8129 - 8941 ↓
AUC 0.716 0.770 0.510 0.830
p-value† <0.0001 <0.0001 0.870 <0.0001
↓ = Decreased intensity in cases compared to controls, ↑ = Increased intenstiy in cases compared to controls.
M/z = Mass to Charge ratio, * Exact mass not reported, # Test used not reported, † Mann-Whitney U TestBMC Medical Genomics 2009, 2:4 http://www.biomedcentral.com/1755-8794/2/4
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Therefore we cannot exclude that differences in the sam-
ple handling protocols and differences in handling sam-
ples of cases and controls in other studies have caused the
inconsistent results.
In this study we also examined the relationships between
a number of patient and tumor characteristics and peak
intensities in order to find possible explanations for the
inconsistencies in the literature. Most characteristics
appeared to be unrelated to peak intensity, however we
did find a relation between the intensity of one of the
peaks and menopause status. The previous studies did not
provide information on menopause status [3,4] or did not
investigate this relation [2].
We also investigated the relations between the intensities
of the several peaks and HER2/neu and p53 expression
and ER and PR status. Since breast cancer is such a hetero-
geneous disease, factors causing this heterogeneity, like
HER2/neu and p53 expression and ER and PR status [17],
should be investigated when searching for potential
biomarkers for breast cancer. It is possible that different
biomarkers are needed to distinguish different molecular
subtypes of breast cancer. No relations between peak
intensities and ER/PR status were observed in the studies
by Mathelin et al. [2] and by Li et al. [4], neither they were
in our study. However, we did find a borderline statisti-
cally significant relation between p53 expression and m/z
8129. It might be possible that differences in ratio of the
several molecular subtypes of breast cancer between the
studies have led to inconsistencies in the results. However,
no information about p53 expression was available in the
previous studies [2-4].
Conclusion
In conclusion, in this study we were able to detect of all
three previously reported proteins [2-4]. Most remarka-
bly, two out of the three proteins seemed to be discrimi-
natory but not always in the same direction as in the
previous studies. We did not find an immediate explana-
tion for these inconsistencies, but it probably illustrates
the susceptibility of proteins to external circumstances.
For future studies, more effort should be put into the col-
lection of blood samples of cases and controls with the
use of standardized and high quality procedures. Also, a
distinction should be made between molecular subtypes
of breast cancer in the search for specific tumor markers.
The proteins investigated in this study have not yet been
proven to be reliable markers for breast cancer.
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